Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonicog Alfa (rVWF) Prophylaxis in Children With Severe Von Willebrand Disease
NCT05582993Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Nov 2024
- Primary completion
- Apr 2030
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
A Phase 3 trial of vonicog alfa in von Willebrand disease (VWD), sponsored by Takeda. Started Nov 2024; status: recruiting.
02
Drugs
vonicog alfa
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on NCT05582993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05582993.